Responses
Oncology
Protocol
Intraperitoneal irinotecan with concomitant FOLFOX and bevacizumab for patients with unresectable colorectal peritoneal metastases: protocol of the multicentre, open-label, phase II, INTERACT-II trial
Compose a Response to This Article
Other responses
No responses have been published for this article.